Aquivia Health Tirzepatide Review: Cost, Brand Access & Honest Verdict (2026)

Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the unusual option to step up to branded Ozempic or Zepbound from the same account — a side-by-side choice most compounded-only providers don't offer. Clinical care runs through Open Loop Healthcare Partners, PC, a network independently confirmed elsewhere on this site. Every fact here comes from the company's own published program.

What Aquivia Health is

Aquivia Health is a self-pay telehealth platform, with clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network already documented behind other providers on this site. Named leadership is disclosed: Steven Bishop, MD (CMO), Phillip Gray, PharmD (Chief Pharmacist), and Tom Foster (President) — a real, checkable level of transparency most compounded-only competitors don't offer.

What Aquivia Health costs

Tirzepatide is priced at $179/month. Itemized pricing is published: compounded semaglutide $149/month, tirzepatide $179/month, brand Ozempic $1,299, brand Zepbound $1,399 — genuinely both compounded and branded GLP-1s offered side by side, unusual for a provider in this category.

The warning-letter claim, checked and cleared

An earlier version of this review left an unconfirmed FDA warning-letter claim standing against Aquivia Health, sourced from prior research rather than from FDA. That claim is withdrawn, and this section is the correction: there is no FDA warning letter on record for this company. On 7 August 2026 FDA's complete warning-letter index was paged in full — all 3,651 rows — and matched offline on the company column, the column FDA itself files a letter under, for both "Aquivia" and "CatalystMD", the legal/brand entity the site's own schema data names. Neither returns a match. SkinnyRx's own February 2026 letter came back in that same pass as a positive control, which is what makes the zeroes a result rather than a search that quietly failed. To be exact about what that does and does not establish: as of 7 August 2026, FDA's own warning-letter database holds no warning letter on file for this company. It is not a clean bill of health on anything else — the trade-offs below still stand, including the brand-name discrepancy — and you can search the database yourself at fda.gov.

Brand confusion worth knowing about

Aquivia Health's own site schema names "CatalystMD" as the underlying legal/brand entity, while the customer-facing name is Aquivia Health — worth knowing if you're trying to independently verify this company's regulatory or business record under one name and finding nothing, since the relevant records may sit under the other.

The brand-vs-compounded question

Aquivia Health offers both compounded tirzepatide and genuine brand-name Ozempic and Zepbound — a real, itemized side-by-side choice. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials, while the brand products are. See our Zepbound cost and savings guide for the branded benchmark.

How the care model holds up

Aquivia Health's real strengths, and: named clinical leadership, a verified MSO network (Open Loop Healthcare Partners), itemized pricing across both compounded and brand tiers, and no separate consultation fee. The trade-offs: no public list of states served; no named 503A compounding pharmacy partner, limiting licensure verification; no LegitScript, PCAB, or BBB trust badges visible; and a brand-name discrepancy (CatalystMD vs. Aquivia Health) worth understanding when researching the company. What is no longer a trade-off is the regulatory claim: no FDA warning letter is on record for this company, checked against FDA's complete index on the company column. As with any GLP-1 program, research this provider's record yourself under both names before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Aquivia Health's named leadership and side-by-side compounded/brand pricing are genuine strengths, and the warning-letter claim this review once left hanging over the company is now cleared — no such letter is on record at FDA under either name. The real open item is the brand-name discrepancy (CatalystMD), worth researching directly before you commit. If you want a similarly transparent provider this review confirmed more fully, compare it against RxSpan MD. See our best tirzepatide providers ranking for the full field.